Skip to main contentSkip to main content
info@smcsalud.org
Educational Guide

Early Alzheimer's Evaluation

An educational guide for families and caregivers exploring early Alzheimer's evaluation options — early diagnosis, mild cognitive impairment assessment, and Cuba's comprehensive evaluation program. Information to support informed decisions, in consultation with your healthcare provider.

Cuban biotech innovation Cognitive rehabilitation For US families & caregivers
7.4M
Americans 65+ with Alzheimer's (2026)
13M
Projected by 2050 (Alzheimer's Assn.)
$409B
Annual US dementia care cost (2026)
4–8 wks
Cuba program cycles (individualized)

Educational Resource — Not Medical Advice

The information on this page is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with your qualified healthcare provider before making decisions about treatment options.

We do not target, identify, or retarget individuals based on health conditions. This content is intended for families and caregivers seeking information about international treatment options, and is discoverable through organic search.

Why Evaluate Early?

The Importance of

Early Alzheimer's evaluation — at the stage of mild cognitive impairment (MCI) or early-stage dementia — provides the greatest opportunity to explore all treatment options and plan ahead. The Alzheimer's Association emphasizes that early and accurate diagnosis is valuable for patients and families.

Mild Cognitive Impairment

MCI is an early stage of cognitive change that may or may not progress to Alzheimer's. Evaluation at this stage provides a baseline and helps monitor progression.

Early-Stage Alzheimer's

Early-stage diagnosis allows families to explore all treatment options while the patient can actively participate in decisions.

Differential Diagnosis

Early evaluation helps distinguish Alzheimer's from other forms of dementia, reversible causes, and normal aging.

Treatment Planning

Early diagnosis opens the door to all available options — domestic and international — including Cuba's neuroprotective therapy program.

What Early Evaluation Includes

Components of

Early Alzheimer's evaluation is comprehensive and multidisciplinary. Cuba's program provides a thorough assessment designed to identify cognitive changes early and accurately.

Detailed Cognitive Testing

Sensitive neuropsychological tests that can detect subtle cognitive changes before they become obvious in daily life.

Neuroimaging

MRI to assess brain volume and rule out other causes; PET imaging for amyloid/tau where available.

Medical History

Review of risk factors, family history, medications, and symptom progression timeline.

Specialist Review

Neurologist consultation to integrate findings, provide a diagnosis, and discuss all available options.

Family Education

Education and support for family members on what the diagnosis means and what to expect.

Monitoring Plan

A plan for ongoing monitoring to track any progression and adjust care as needed.

Cuban Biotechnology

NeuralCIM® — Advanced Therapy for Alzheimer's Disease

Supporting memory, preserving identity, restoring quality of life.

Cuban biotechnology, now within reach for patients from around the world. Speak with our coordinators about NeuralCIM Alzheimer's care in Cuba.

Cuba's Approach

The Cuban Neuro-Care Program

Cuba has built a neuro-care program that combines its own biotechnology — NeuralCIM, a low-sialic-acid erythropoietin developed by the Center for Molecular Immunology — with intensive, multidisciplinary rehabilitation. This approach is not available in the United States.

  • NeuralCIM neuroprotective therapy — a Cuban biotechnology innovation
  • Intensive cognitive rehabilitation delivered by neuropsychologists
  • Multidisciplinary team: neurologists, therapists, and specialized nursing
  • 4–8 week individualized program cycles with continuous monitoring
  • Coordinated aftercare and handover to your US physician
  • English-speaking coordinators at every step

NeuralCIM®

Cuban biotechnology

Low-sialic-acid erythropoietin developed by Cuba's Center for Molecular Immunology (CIM), applied in neuro-care for its neurotrophic and neuroprotective properties.

4–8 Week Cycles

Multidisciplinary Team

Your Journey to Cuba

From First Inquiry to Safe Return Home

01

Contact Us

Share your medical information and history through our inquiry form or coordinators.

02

Free Evaluation

Our neurology experts review your US records and design a personalized treatment plan.

03

Travel Coordination

We assist with e-Visa, flights, and comfortable accommodation in Cuba for patient and family.

04

Treatment

Receive personalized neuro-care with continuous, multidisciplinary support.

05

Aftercare

Coordinated handover to your US physician with a long-term monitoring plan.

Frequently Asked Questions

Your Questions Answered

Request a Free Clinical Evaluation

Share your medical information with our neuro-care team and receive a personalized evaluation — often within 24–48 hours. No obligation, no travel required to get started.